Tag: Xeralto

FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

Peripheral/Endo Regulatory by 0 comments

XARELTO® is available as both an oral tablet and oral suspension formulation for use in appropriate children less than 18 years of age Convenient oral suspension formulation advances standard of care for children; alleviates administration challenges found with injectable alternatives […]

Continue Reading →

Bayer (BAY) Release: In Canadian-Led Phase III Clinical Study, Xarelto® When Combined With ASA Significantly Lowered The Combined Risk Of Stroke, Cardiovascular Death, And Heart Attack In Patients With Chronic Coronary Or Peripheral Artery Disease By 24%

Coronary/Structural Heart by 0 comments

  Bleeding rates were low, and while major bleeding was increased, notably, there was no significant increase in intracranial or fatal bleeding1. This combination regimen demonstrated a substantial improvement in net clinical benefit of 20%1. Data from Canadian-led COMPASS study, […]

Continue Reading →